ЭФФЕКТИВНОСТЬ И ПЕРЕНОСИМОСТЬ ПЕРАМПАНЕЛА У ПОДРОСТКОВ И ВЗРОСЛЫХ С РЕЗИСТЕНТНОЙ ФОКАЛЬНОЙ ЭПИЛЕПСИЕЙ. ОБЗОР ДАННЫХ МЕЖДУНАРОДНЫХ ИССЛЕДОВАНИЙ

1. Kwan P., Brodie M.J. Effectiveness of first antiepileptic drug. Epilepsia. 2001; 42 (10): 1255-60.

2. Schiller Y., Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008; 70 (1): 54-65.

3. Rogawski M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents. 2011; 11: 56-63.

4. Hanada T. et al. Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011; 52: 1331-40.

5. French J.A. et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012; 79: 589-96.

6. French J.A. et al. Evaluation of adjunctive perampanel in patients with refractory partial- onset seizures: Results of randomized global phase III study 305. Epilepsia. 2013; 54: 117-25.

7. Krauss G.L. et al. Randomized phase III study 306: adjunctive perampanel for partial onset seizures. Neurology. 2012; 78: 1408-15.

8. Steinhoff B.J. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia. 2013; 54 (8): 1481-9.

9. Krauss G.L. et al. Perampanel, a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307. Epilepsia. 2013; 54: 126.